About Crinetics Pharmaceuticals, Inc.
https://www.crinetics.comCrinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors.
CEO
R. Scott Struthers
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 150
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Jefferies
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
Oppenheimer
Outperform
Grade Summary
Showing Top 6 of 11
Price Target
Institutional Ownership
FMR LLC
Shares:14.19M
Value:$786.27M
VANGUARD GROUP INC
Shares:9.17M
Value:$508.21M
WELLINGTON MANAGEMENT GROUP LLP
Shares:8.38M
Value:$464.53M
Summary
Showing Top 3 of 252
About Crinetics Pharmaceuticals, Inc.
https://www.crinetics.comCrinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $143K ▼ | $142.73M ▲ | $-130.09M ▼ | -90.97K% ▼ | $-1.38 ▼ | $-141.57M ▼ |
| Q2-2025 | $1.03M ▲ | $130.14M ▲ | $-115.64M ▼ | -11.22K% ▲ | $-1.23 ▼ | $-128.15M ▼ |
| Q1-2025 | $361K ▲ | $111.77M ▲ | $-96.77M ▼ | -26.81K% ▼ | $-1.04 ▼ | $-110.48M ▼ |
| Q4-2024 | $0 | $94.75M ▲ | $-80.59M ▼ | 0% | $-0.88 ▲ | $-93.96M ▼ |
| Q3-2024 | $0 | $87.8M | $-76.83M | 0% | $-0.96 | $-87.03M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $1.09B ▼ | $1.2B ▼ | $123.86M ▲ | $1.07B ▼ |
| Q2-2025 | $1.2B ▼ | $1.29B ▼ | $118.05M ▲ | $1.17B ▼ |
| Q1-2025 | $1.27B ▼ | $1.36B ▼ | $107.33M ▼ | $1.25B ▼ |
| Q4-2024 | $1.35B ▲ | $1.43B ▲ | $109.79M ▲ | $1.32B ▲ |
| Q3-2024 | $862.67M | $937.37M | $104.39M | $832.98M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-130.09M ▼ | $-110.72M ▼ | $164.81M ▲ | $3.08M ▼ | $57.17M ▲ | $-111.58M ▼ |
| Q2-2025 | $-115.64M ▼ | $-85.85M ▲ | $37.95M ▲ | $7.05M ▲ | $-40.84M ▲ | $-89.05M ▲ |
| Q1-2025 | $-96.77M ▼ | $-88.45M ▼ | $-85.96M ▲ | $4.44M ▼ | $-169.98M ▼ | $-89.69M ▼ |
| Q4-2024 | $-80.59M ▼ | $-64.67M ▼ | $-542.09M ▼ | $554.04M ▲ | $-52.72M ▼ | $-65.7M ▼ |
| Q3-2024 | $-76.83M | $-60.8M | $20.6M | $55.3M | $15.11M | $-61.32M |
CEO
R. Scott Struthers
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 150
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Jefferies
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
Oppenheimer
Outperform
Grade Summary
Showing Top 6 of 11
Price Target
Institutional Ownership
FMR LLC
Shares:14.19M
Value:$786.27M
VANGUARD GROUP INC
Shares:9.17M
Value:$508.21M
WELLINGTON MANAGEMENT GROUP LLP
Shares:8.38M
Value:$464.53M
Summary
Showing Top 3 of 252